NextGen Group has announced that due to an inability to secure additional financing it will likely take steps to wind down its business unless it is able in the near future to find a buyer for its principal subsidiary, protein biomarker firm NextGen Sciences.

The company noted that it has not yet received any acceptable offers for NextGen Sciences and that even if it is sold, "it is unlikely that it will generate sufficient cash to settle all the company's outstanding creditors in full."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.